UroGen Q2 2021 Earnings Report
Key Takeaways
UroGen Pharma reported a net product revenue of $13.0 million for Jelmyto in the second quarter of 2021, representing a 70% growth over the first quarter. The company's Phase 3 ATLAS trial for UGN-102 continues to enroll patients, with nearly 100 global centers activated. UroGen also commenced Jelmyto geographic expansion efforts with a Neopharm license in Israel.
Jelmyto net product revenue reached $13.0 million in Q2 2021, a 70% increase from Q1 2021.
Nearly 100 global centers are activated for the Phase 3 ATLAS trial of UGN-102.
UroGen initiated Jelmyto geographic expansion with a Neopharm license in Israel.
A non-human primate toxicity study for UGN-301 commenced.
UroGen
UroGen
UroGen Revenue by Segment
Forward Guidance
The Company continues to anticipate operating expenses in the range of $155 to $165 million, including non-cash share-based compensation expense of $24 to $28 million, subject to market conditions.